Rasagiline prodrug - Guangzhou Henovcom Bioscience
Alternative Names: HNC-364Latest Information Update: 09 Oct 2024
At a glance
- Originator Guangzhou Henovcom Bioscience
- Class Amines; Antiparkinsonians; Indans; Small molecules
- Mechanism of Action Monoamine oxidase B inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I Parkinson's disease
Most Recent Events
- 15 Apr 2024 Guangzhou Henovcom Bioscience completes tha Phase-I clinical trials in Parkinson's disease (In volunteers) in USA (IM) (NCT05523570)
- 06 Sep 2022 Guangzhou Henovcom Bioscience has patent protection for HNC 364 in China and Japan (Guangzhou Henovcom Bioscience pipeline, September 2022)
- 22 Aug 2022 Phase-I clinical trials in Parkinson's disease (In volunteers) in USA (IM) (NCT05523570)